Financial Data and Key Metrics Changes - The company reported a net loss of $67.6 million or $0.10 per share for Q1 2025, compared to a net loss of $81.8 million or $0.12 per share for the same period in 2024, indicating an improvement in financial performance [25] - Total revenues for 2025 are expected to be between $675 million and $685 million, with costs and expenses projected between $825 million and $875 million, excluding nonrecurring expenses related to restructuring [31][32] - Operating loss for the Diagnostics segment was $23.9 million in Q1 2025, an improvement from an operating loss of $34.4 million in Q1 2024 [21] Business Line Data and Key Metrics Changes - Diagnostics segment revenue was $102.8 million for Q1 2025, down from $126.9 million in Q1 2024, primarily due to the sale of assets to LabCorp [20] - The Pharmaceutical segment revenue increased to $47.1 million in Q1 2025 from $46.8 million in Q1 2024, with product revenue slightly decreasing to $34.8 million from $38.1 million [22] - BioReference's 4Kscore test reported a 14.5% growth year over year, indicating strong performance in its core testing capabilities [12] Market Data and Key Metrics Changes - The company anticipates that the remaining BioReference business will generate approximately $320 million in revenue for 2024 after the sale of the oncology business [12] - The foreign currency environment has impacted revenue, but profitability remains stable due to disciplined operating expense management [22] Company Strategy and Development Direction - The company is focused on advancing its strategic initiatives, including the sale of BioReference's oncology business to LabCorp, which is expected to enhance profitability [6][9] - A $100 million increase in the common stock repurchase program was approved, bringing the total to $200 million, reflecting the belief that shares are undervalued [9] - The company is working on operational efficiencies and cost reduction initiatives, targeting an additional $10 million in annualized cost savings [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving profitability for BioReference by the end of 2025, following the completion of the LabCorp transaction [30] - The company expects to continue navigating challenges in the pharmaceutical segment, particularly related to foreign currency fluctuations and the competitive landscape [28] Other Important Information - The company ended Q1 2025 with approximately $450 million in cash and cash equivalents, bolstered by the exit from a position in GNDX [26] - A convertible debt exchange was completed, eliminating $159.2 million of outstanding convertible notes [26] Q&A Session Summary Question: What are some possible explanations for the negative dynamics for ENGENLA? - Management indicated that the growth rates for prescriptions continue, suggesting that the issues are likely related to the commercial environment rather than competition [34] Question: Could you provide a rough timeline about the development program of the GLP-one glucagon tablet candidate? - The IND is expected to be filed by the end of this year or early next year, with Phase one trial results anticipated by the end of 2026 [39] Question: What are the next steps for the subcutaneous obesity program and NASH program? - Both programs are in the pre-IND phase, with plans to enter Phase I trials focusing on safety and pharmacological behavior [60] Question: Can you comment on the convertible notes and secured notes? - Approximately $129 million of principal remains outstanding on convertible notes, with pro forma shares increasing to about $790 million [46] Question: What is the expected revenue from BARDA? - The revised guidance for BARDA revenue is now between $38 million and $44 million, down from previous estimates [80]

Financial Data and Key Metrics Changes - The company reported a net loss of $67.6 million or $0.10 per share for Q1 2025, compared to a net loss of $81.8 million or $0.12 per share for the same period in 2024 [24] - Total revenue for Q1 2025 was $149.9 million, a decrease from $173.7 million in Q1 2024, primarily due to the sale of assets to LabCorp [18][20] - Operating loss for Q1 2025 was $58.7 million, compared to an operating loss of $62.1 million in Q1 2024 [24] Business Line Data and Key Metrics Changes - Diagnostics segment revenue was $102.8 million for Q1 2025, down from $126.9 million in Q1 2024, largely due to the LabCorp transaction [18][20] - The Pharmaceutical segment revenue increased slightly to $47.1 million in Q1 2025 from $46.8 million in Q1 2024, with product revenue including international sales at $34.8 million [20] - The 4Kscore test in the Diagnostics segment reported a 14.5% year-over-year growth [10] Market Data and Key Metrics Changes - The company anticipates total revenues for 2025 to be between $675 million and $685 million, with service revenue projected between $400 million and $425 million [29] - Revenue from products is expected to be between $165 million and $175 million, while other revenue, including Pfizer gross profit share, is estimated between $30 million and $40 million [29] Company Strategy and Development Direction - The company is focused on advancing its strategic initiatives, including the sale of BioReference's oncology business to LabCorp, which is expected to enhance profitability [5][9] - A $100 million increase in the common stock repurchase program was approved, bringing the total to $200 million, indicating confidence in the company's undervalued shares [7] - The company aims to reach profitability within the year and is executing a multi-year program to improve operational efficiencies in the Diagnostics segment [12][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to drive value for shareholders despite challenges in the commercial environment affecting product sales [5][20] - The company expects to incur additional non-recurring costs of $5 million in Q2 2025, primarily related to severance [28] - Management remains optimistic about the progress of its pharmaceutical programs and the potential for profitability in the Diagnostics segment post-LabCorp transaction [18][28] Other Important Information - The company ended Q1 2025 with approximately $450 million in cash and equivalents, having exited its position in GNDX, adding $51 million to its cash balance [25] - The company completed a convertible debt exchange, eliminating $159.2 million of outstanding convertible notes [25] Q&A Session Summary Question: What are some possible explanations for the negative dynamics for ENGENLA? - Management indicated that the growth rates for prescriptions continue, suggesting the issue is likely related to the commercial environment rather than competition [33] Question: Could you comment on why Pfizer withdrew their EU application for the adult setting? - Management noted that Pfizer is focusing on pediatric indications due to the larger market size, which influenced their decision [34] Question: Could you provide a rough timeline about the development program of the GLP-oneglucagon tablet candidate? - The IND is expected to be filed by the end of this year or early next year, with Phase one trial results anticipated by the end of 2026 [37][38] Question: Can you give us a sense of the Diagnostic business and BioReference? - Management confirmed that the remaining business is expected to generate between $310 million and $320 million on an annualized basis [45] Question: What are the next steps for the subcutaneous obesity program and NASH program? - Both programs are in the pre-IND phase, with plans to enter Phase I trials soon, focusing on safety and pharmacological behavior [56][57]

Exhibit 99.1 OPKO Health Reports First Quarter 2025 Business Highlights and Financial Results Conference call begins at 4:30 p.m. Eastern time today MIAMI (April 30, 2025) – OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three months ended March 31, 2025. Highlights from the first quarter of 2025 and recent weeks include the following: ● Signed definitive agreement with Labcorp to sell oncology and related clinical testing assets of BioReference Health (BioReferenc ...

Core Insights - OPKO Health, Inc. reported a consolidated total revenue of $149.9 million for Q1 2025, a decrease from $173.7 million in Q1 2024, with an operating loss of $67.2 million compared to $71.5 million in the previous year [2][3][14] - The company signed a definitive agreement with Labcorp to sell oncology and related clinical testing assets for up to $225 million, expected to close in the second half of 2025 [2] - OPKO entered into a collaboration agreement with Entera Bio to develop an oral GLP-1/glucagon tablet candidate for obesity and metabolic disorders, with OPKO holding a 60% ownership interest [2] - The company authorized an additional $100 million for its common stock repurchase program, increasing the total capacity to $200 million [2] Financial Performance - Total revenues for Q1 2025 were $149.9 million, down from $173.7 million in Q1 2024, with revenues from services at $102.8 million compared to $126.9 million in the prior year [14] - Revenue from products was $34.8 million, a decrease from $38.1 million in Q1 2024, primarily due to unfavorable foreign currency exchange rates and a decline in Rayaldee sales [3][14] - The net loss for Q1 2025 was $67.6 million, or $0.10 per share, compared to a net loss of $81.8 million, or $0.12 per share, in Q1 2024 [14] Operational Highlights - The company is advancing its immuno-oncology and immunology portfolio, with multiple clinical candidates in development, including MDX2001, MDX2003, and MDX2004 [2] - Enrollment and dosing for a Phase 1 Epstein-Barr virus vaccine trial, developed in collaboration with Merck, have commenced [2] - OPKO's cash, cash equivalents, and restricted cash totaled $449.7 million as of March 31, 2025, following the sale of GeneDx shares [8] Strategic Initiatives - The sale of BioReference's oncology assets is part of OPKO's strategy to streamline operations while maintaining core clinical testing services, which generated approximately $300 million in revenue for 2024 [2] - The collaboration with Entera Bio aims to leverage OPKO's proprietary technology to address obesity and metabolic disorders, indicating a focus on innovative therapeutic solutions [2] - The company continues to pursue share repurchase programs as part of its capital allocation strategy, reflecting confidence in its long-term value [2]

MIAMI, April 17, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2025 after the close of the U.S. financial markets on Wednesday, April 30, 2025. OPKO’s senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast on April 30th beginning at 4:30 p.m. Eastern time. CONFERENCE CALL & WEBCAST INFORMATION OPKO encourages participants ...

Core Viewpoint - OPKO Health, Inc. has authorized a $100 million increase to its common stock repurchase program, raising the total capacity to $200 million, reflecting the company's belief that its shares are undervalued and demonstrating confidence in its strategic direction [1][2]. Summary by Sections Stock Repurchase Program - The Board of Directors has approved an increase of $100 million to the existing stock repurchase program, bringing the total to $200 million [1]. - Approximately $41 million of OPKO's common stock has already been repurchased since the program's initiation in July 2024 [1]. Management's Perspective - The CEO, Phillip Frost, stated that the share buyback supports the company's strategy and ongoing pipeline advancements while aiming for profitability in the diagnostic segment [2]. - The company plans to repurchase shares through various methods, including open market purchases and block trades, without any obligation to repurchase a specific number of shares [2]. Financial Position - OPKO expects to fund the repurchase program using existing cash and future cash flows, with approximately 671.6 million shares outstanding as of February 24, 2025 [3]. - The total repurchase authorization represents about 14% of the outstanding shares at the current stock price [3]. Company Overview - OPKO Health is a multinational biopharmaceutical and diagnostics company focused on establishing leading positions in rapidly growing markets through its proprietary technologies and expertise in discovery, development, and commercialization [4].

Core Viewpoint - Labcorp has entered into an agreement to acquire select assets from OPKO Health's subsidiary, BioReference Health, which will enhance its oncology diagnostic capabilities and expand its portfolio in cancer care [1][3]. Financial Details - The acquisition price is up to $225 million, comprising $192.5 million payable at closing and up to $32.5 million in performance-based earnouts. This deal is expected to be accretive to Labcorp's earnings in the first year [2]. Acquisition Specifics - Labcorp will acquire BioReference Health's laboratory testing businesses focused on oncology, which currently generate annual revenues of approximately $85 million to $100 million. The transaction includes customer accounts and other operating assets [3]. Operational Impact - The acquisition is expected to enhance access to Labcorp's laboratory services and testing capabilities for patients and healthcare providers. BioReference Health's operations will include core clinical testing in New York and New Jersey, along with its 4Kscore franchise [4]. Regulatory and Closing Timeline - The transaction is subject to customary closing conditions and state regulatory approvals, with an expected closing in the second half of 2025 [5]. Industry Prospects - The global cancer diagnostics market is projected to grow at a compound annual growth rate of 6.14% from 2025 to 2030, driven by increasing cancer prevalence and advancements in diagnostic technologies [6]. Recent Developments by Labcorp - Labcorp recently launched Labcorp Plasma Complete, a liquid biopsy test for advanced solid tumors, and expanded its laboratory in Raritan, NJ, adding 110,000 square feet of advanced space [6][7]. Competitive Landscape - Labcorp faces competition from major players like Illumina, which is advancing cancer genomics, and NeoGenomics, which is expanding its presence in the Northeast through acquisitions and collaborations [8][10].

Financial Position - As of December 31, 2024, the company had cash, cash equivalents, and restricted cash totaling $445.6 million[165]. - Total assets increased to $2,200,212,000 in 2024, up from $2,011,698,000 in 2023, reflecting a growth of 9.4%[508]. - Total liabilities rose to $834,764,000, compared to $622,479,000 in 2023, marking an increase of 34.0%[508]. - Cash and cash equivalents significantly increased to $431,936,000 from $95,881,000, representing a growth of 350.5%[508]. - The company’s cash, cash equivalents, and restricted cash at the end of the period stood at $445.615 million, a significant increase from $95.881 million at the beginning of the period[519]. Revenue and Profitability - Total revenues for 2024 decreased to $713,142,000, down 17.4% from $863,495,000 in 2023[510]. - Revenue from services was $480,667,000, a decline of 6.7% compared to $515,275,000 in 2023[510]. - The company reported a net loss of $53.224 million for the year ended December 31, 2024, compared to a net loss of $188.863 million in 2023, indicating a significant improvement[519]. - The company reported a comprehensive loss of $71,324,000 for 2024, compared to a comprehensive loss of $183,570,000 in 2023[513]. Regulatory and Compliance Risks - The company is required to comply with extensive regulatory standards, including CLIA and ISO certifications, which could delay production and lead to fines if not met[196]. - The company must maintain compliance with current Good Manufacturing Practices (cGMP) regulations, which include quality control and assurance requirements[257]. - The company is subject to numerous federal and state regulations, including anti-kickback laws and false claims laws, which could lead to penalties if not complied with[260]. - The company faces potential civil or criminal penalties for non-compliance with laws and regulations, which could significantly impact its financial condition and operations[262]. - The company is subject to scrutiny regarding the handling and disposal of medical waste, with potential fines and penalties for non-compliance[268]. Clinical and Product Development - The success of the company's product candidates is uncertain, with risks of failure in clinical trials and regulatory approvals[171]. - The FDA approved NGENLA (Somatrogon (hGH-CTP)) for the treatment of pediatric GHD in June 2023, but commercial success in the U.S. is uncertain[179]. - The global phase 3 trial for Somatrogon (hGH-CTP) met its primary endpoint of non-inferiority to daily Genotropin® for injection, showing higher height standard deviation scores at six and twelve months[178]. - The company has secured regulatory approvals for Somatrogon (hGH-CTP) in over 50 markets, including the U.S. and EU, indicating strong market expansion potential[522]. Funding and Financial Challenges - The company may require additional funding, which may not be available on acceptable terms, potentially impacting its operations and clinical trials[166]. - The company has a history of operating losses and may not achieve profitability in the near future, with limited revenue from proprietary pharmaceutical products[164]. - The company may face significant dilution if it raises additional funds through equity securities[170]. - The company completed a private offering of $250 million aggregate principal amount of senior secured notes on July 17, 2024[168]. Market and Competitive Risks - The company faces risks from competitors developing more effective or less expensive products, which could negatively impact revenues and profitability[187]. - The introduction of generic competitors could significantly impact the company's revenues and profitability, as they typically offer lower-priced alternatives[208]. - The healthcare industry is experiencing consolidation, leading to fewer but larger insurance plans with increased bargaining power over clinical testing providers[221]. Management and Operational Risks - The departure of the Chairman and CEO, Phillip Frost, could have a material adverse effect on the company's business and financial condition due to his reputation and role in attracting business opportunities[204]. - The company relies on third-party manufacturers for its products, and any failure in their performance could lead to significant operational disruptions and financial losses[209]. - The complexity of billing for laboratory testing services may lead to revenue losses if not managed properly, including potential penalties and recoupments from payors[214]. Legal and Cybersecurity Risks - The company has faced legal actions and government investigations that could result in substantial monetary damages and negatively impact its reputation and funding[246]. - The company has implemented cybersecurity measures, but remains vulnerable to evolving cyber threats that could impact its operations and reputation[219]. - Cybersecurity threats to the company's IT systems could disrupt operations and lead to unauthorized access to confidential information, adversely affecting business operations[218]. International Operations and Currency Risks - The company is subject to risks associated with currency fluctuations, which can adversely affect margins on international sales and overall financial performance[290]. - The company operates in a politically and economically unstable environment in Israel, which may adversely affect its operations and revenue[288]. - The company’s international business is subject to various laws and regulations, and failure to comply could result in administrative, civil, or criminal liabilities[295]. Shareholder and Equity Information - Approximately 55.46% of the company's outstanding voting securities are beneficially owned by directors, executive officers, and principal stockholders, with Phillip Frost owning about 36.97%[302]. - As of January 31, 2025, there is a significant short position of approximately 88,641,089 shares, representing about 13.2% of the outstanding Common Stock, which could exert downward pressure on the stock price[303].

Core Insights - OPKO Health, Inc. reported earnings per share (EPS) of $0.01 in Q4 2024, a significant improvement from a loss of $0.09 in the same period last year and better than the Zacks Consensus Estimate of a loss of $0.11 [1][2] - The company’s full-year 2024 loss per share was $0.08, narrower than the loss of $0.25 expected by analysts [2] Revenue Performance - OPKO Health's revenues for Q4 2024 were $183.6 million, reflecting a year-over-year increase of 0.9% and exceeding the Zacks Consensus Estimate by 18.4% [3] - Full-year revenues for 2024 totaled $713.1 million, down 17.4% from 2023 but still beating the Zacks Consensus Estimate by 4.2% [3] Segment Analysis - In the Diagnostics segment, service revenues were $103.1 million, down 16.9% year-over-year due to lower clinical test volumes [5] - The Pharmaceuticals segment saw product revenues decline by 13% to $37.4 million, impacted by unfavorable foreign currency exchange rates [6] - Revenues from the transfer of intellectual property and other sources surged by 193.2% to $43.1 million, driven by milestone payments related to clinical trials [7] Margin and Expense Analysis - Gross profit for the quarter increased by 89.3% to $84.6 million, with gross margin expanding by 2150 basis points to 46.1% [8] - Selling, general, and administrative expenses decreased by 8.1% to $67 million, while research and development expenses rose by 56.7% to $30.4 million [8] Financial Position - OPKO Health ended 2024 with cash and cash equivalents of $431.9 million, a significant increase from $95.9 million at the end of 2023 [11] Future Guidance - For 2025, OPKO Health expects total revenues between $675 million and $700 million, with the Zacks Consensus Estimate at $675.2 million [12] - The company anticipates service revenues to be between $405 million and $425 million, product sales between $165 million and $175 million, and other revenues between $80 million and $95 million [13] Overall Assessment - The company demonstrated better-than-expected results in Q4 2024, with strong revenue growth from intellectual property transfers and improved gross margins [14] - However, lower revenues from products and services, particularly the decline in RAYALDEE sales, raised concerns [16]

Core Insights - OPKO Health reported revenue of $183.6 million for the quarter ended December 2024, reflecting a year-over-year increase of 0.9% and surpassing the Zacks Consensus Estimate of $155.14 million by 18.35% [1] - The company achieved an EPS of $0.01, a significant improvement from -$0.09 in the same quarter last year, resulting in an EPS surprise of 109.09% against the consensus estimate of -$0.11 [1] Revenue Breakdown - Revenue from the transfer of intellectual property and other sources was $43.10 million, exceeding the average estimate of $14.89 million by analysts, marking a year-over-year increase of 193.2% [4] - Revenue from products was reported at $37.40 million, which fell short of the average estimate of $42.96 million, representing a year-over-year decline of 13% [4] - Revenue from services amounted to $103.10 million, slightly above the estimated $97.29 million, but showed a year-over-year decrease of 17% [4] Stock Performance - OPKO Health's shares have returned +10.7% over the past month, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]